Targeting one-carbon metabolism requires mTOR inhibition: a new therapeutic approach in osteosarcoma

The rate-limiting enzyme of serine biosynthesis, 3-phosphoglycerate dehydrogenase (PHGDH), contributes to rapid growth and proliferation when it is overexpressed in cancer. We recently described the metabolic adaptations that occur upon PHGDH inhibition in osteosarcoma. PHGDH inhibition causes metab...

Descripción completa

Detalles Bibliográficos
Autores principales: Rathore, Richa, Van Tine, Brian
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Taylor & Francis 2021
Materias:
Author’s Views
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8128185/
https://www.ncbi.nlm.nih.gov/pubmed/34027041
http://dx.doi.org/10.1080/23723556.2021.1902250
_version_ 1783694070299754496
author Rathore, Richa
Van Tine, Brian
author_facet Rathore, Richa
Van Tine, Brian
author_sort Rathore, Richa
collection PubMed
description The rate-limiting enzyme of serine biosynthesis, 3-phosphoglycerate dehydrogenase (PHGDH), contributes to rapid growth and proliferation when it is overexpressed in cancer. We recently described the metabolic adaptations that occur upon PHGDH inhibition in osteosarcoma. PHGDH inhibition causes metabolite accumulation that activates the mechanistic target of rapamycin (mTOR) signaling, sensitizing osteosarcoma to non-rapalog mTOR inhibition.
format Online
Article
Text
id pubmed-8128185
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Taylor & Francis
record_format MEDLINE/PubMed
spelling pubmed-81281852021-05-21 Targeting one-carbon metabolism requires mTOR inhibition: a new therapeutic approach in osteosarcoma Rathore, Richa Van Tine, Brian Mol Cell Oncol Author’s Views The rate-limiting enzyme of serine biosynthesis, 3-phosphoglycerate dehydrogenase (PHGDH), contributes to rapid growth and proliferation when it is overexpressed in cancer. We recently described the metabolic adaptations that occur upon PHGDH inhibition in osteosarcoma. PHGDH inhibition causes metabolite accumulation that activates the mechanistic target of rapamycin (mTOR) signaling, sensitizing osteosarcoma to non-rapalog mTOR inhibition. Taylor & Francis 2021-03-25 /pmc/articles/PMC8128185/ /pubmed/34027041 http://dx.doi.org/10.1080/23723556.2021.1902250 Text en © 2021 The Author(s). Published with license by Taylor & Francis Group, LLC. https://creativecommons.org/licenses/by-nc-nd/4.0/This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives License (http://creativecommons.org/licenses/by-nc-nd/4.0/ (https://creativecommons.org/licenses/by-nc-nd/4.0/) ), which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited, and is not altered, transformed, or built upon in any way.
spellingShingle Author’s Views
Rathore, Richa
Van Tine, Brian
Targeting one-carbon metabolism requires mTOR inhibition: a new therapeutic approach in osteosarcoma
title Targeting one-carbon metabolism requires mTOR inhibition: a new therapeutic approach in osteosarcoma
title_full Targeting one-carbon metabolism requires mTOR inhibition: a new therapeutic approach in osteosarcoma
title_fullStr Targeting one-carbon metabolism requires mTOR inhibition: a new therapeutic approach in osteosarcoma
title_full_unstemmed Targeting one-carbon metabolism requires mTOR inhibition: a new therapeutic approach in osteosarcoma
title_short Targeting one-carbon metabolism requires mTOR inhibition: a new therapeutic approach in osteosarcoma
title_sort targeting one-carbon metabolism requires mtor inhibition: a new therapeutic approach in osteosarcoma
topic Author’s Views
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8128185/
https://www.ncbi.nlm.nih.gov/pubmed/34027041
http://dx.doi.org/10.1080/23723556.2021.1902250
work_keys_str_mv AT rathorericha targetingonecarbonmetabolismrequiresmtorinhibitionanewtherapeuticapproachinosteosarcoma
AT vantinebrian targetingonecarbonmetabolismrequiresmtorinhibitionanewtherapeuticapproachinosteosarcoma

Ejemplares similares